In summary, NFAT GMCAR WT1TCR-T cells have more potent antileukemic activity than WT1TCR against primary AML cells, which is associated with their enhanced expansion and increased percentage of T cells with less differentiated memory immunophenotype mainly among CD4-positive T cells. This evidence concerns the gene CD4 and acute myeloid leukemia.